ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Antibodies"

  • Abstract Number: 674 • 2013 ACR/ARHP Annual Meeting

    Systemic Sclerosis Disease Subset Is a Better Predictor Of Long Term Outcome Than Autoantibody Profile

    Svetlana I. Nihtyanova1, Voon H. Ong2 and Christopher P. Denton3, 1Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 2Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, 3Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom

    Background/Purpose: Disease subset has been shown to strongly correlate with survival and risk of organ complications in patients with systemic sclerosis (SSc). Nevertheless evidence in…
  • Abstract Number: 683 • 2012 ACR/ARHP Annual Meeting

    Prevalence of Inhibitory or Non-Inhibitory Autoantibodies to Angiotensin Converting Enzyme 2 (ACE2) in Patients with Systemic Lupus Erythematosus

    Yuko Takahashi1, Shiori Haga2, Yukihito Ishizaka2 and Akio Mimori3, 1Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan, 2Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan, 3Department of Intractable Diseases, National Center for Global Health and Medicine, Tokyo, Japan

    Background/Purpose: We previously reported that inhibitory autoantibodies to angiotensin converting enzyme 2 (ACE2) predisposed individuals to connective tissue diseases (i.e., scleroderma or systemic lupus erythematosus…
  • Abstract Number: 665 • 2012 ACR/ARHP Annual Meeting

    Cytokines and Their Relation to Autoantibodies Before Disease Onset in Systemic Lupus Erythematosus

    Catharina Eriksson1 and Solbritt Rantapää Dahlqvist2, 1Department of Clinical Immunology/clinical microbiology, Umeå, Sweden, 2Department of Public Health and Clinical Medicine/Rheumatology, Umeå University Hospital, Umeå, Sweden

    Background/Purpose: Cytokines and autoantibodies are involved in the pathogenesis of systemic lupus erythematosus (SLE). The presence of autoantibodies preceding disease onset by years has been…
  • Abstract Number: 485 • 2012 ACR/ARHP Annual Meeting

    Immunogenicity of Infliximab Is Related to Reduction of Frequency of Infliximab Administration in Rheumatoid Arthritis and Spondyloarthritis Patients

    Mathieu Verdet1, Clément Guillou2, Marie-Laure Potier2, Martine Hiron2, Fabienne Jouen3, Olivier Boyer4, Thierry Lequerré5 and Olivier Vittecoq6, 1Rheumatology, Rouen University Hospital, Bois Guillaume, France, 2Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, 3Immunology, Rouen University Hospital, Rouen Cedex, France, 4Immunology, INSERM U905, University of Rouen, Rouen, France, 5Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 6Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France

    Background/Purpose: To analyze the clinical and biological characteristics associated with presence of antibodies to Infliximab, in rheumatoid arthritis (RA) and spondyloarthritis patients (SpA). Methods: Sera…
  • Abstract Number: 349 • 2012 ACR/ARHP Annual Meeting

    Preliminary Results From a Controlled Study Assessing the Humoral Immune Response to Vaccines in Rheumatoid Arthritis Patients Treated with Tocilizumab

    Clifton O. Bingham III1, Warren C. Rizzo2, Micki Klearman3, Azra Hassanali4, Ruchi Upmanyu5 and Alan J. Kivitz6, 1Rheumatology, Johns Hopkins University, Baltimore, MD, 2Advanced Arthritis Care & Research, Scottsdale, AZ, 3Genentech Inc, South San Francisco, CA, 4Genentech Inc, San Francisco, CA, 5Roche, Welwyn Garden City, United Kingdom, 6Altoona Center for Clinical Research, Duncansville, PA

    Background/Purpose: Tocilizumab (TCZ) is an IL-6–receptor inhibitor for treatment of rheumatoid arthritis (RA) patients (pts). Because TCZ may impact how IL-6 modulates T-cell activation and…
  • Abstract Number: 2659 • 2012 ACR/ARHP Annual Meeting

    An Expanded Repertoire of Anti-Citrullinated Peptide Antibodies Is Associated with Interstitial Lung Disease in Rheumatoid Arthritis

    Jon T. Giles1, Sonye Danoff2, Jeremy Sokolove3, Robert Winchester4, Dimitrios A. Pappas5, Catriona Cramb6, Geoffrey Connors7, Stanley S. Siegelman8, William H. Robinson9 and Joan M. Bathon5, 1Medicine, Columbia University, New York, NY, 2Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, 3Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 4Dept of Medicine & Pathology, Columbia University, New York, NY, 5Columbia University, New York, NY, 6VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, 7Division of Pulmonary and Critical Care Medicine, Yale University, New Haven, CT, 8Department of Radiology, Johns Hopkins University, Baltimore, MD, 9Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA

    Background/Purpose: Interstitial lung disease (ILD) is an outcome with high morbidity and mortality in rheumatoid arthritis (RA).  Citrullinated proteins are observed in these lung tissues;…
  • Abstract Number: 286 • 2012 ACR/ARHP Annual Meeting

    The Association of N-Methyl-D-Aspartate Receptor Antibodies and Neurocognitive Dysfunction in Pediatric Lupus Patients and in the Offspring of Adult Patients with Lupus

    Natasha M. Ruth1, Mary C. Kral2, Stephanie Slan3, Tamara K. Nowling4, Murray H. Passo1 and Gary S. Gilkeson3, 1Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, 2Genetics and Developmental Pediatrics, MUSC, Charleston, SC, 3Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 4Medical University of South Carolina, Charleston, SC

    Background/Purpose: Approximately 1/5 of all systemic lupus erythematosus (SLE) starts in childhood and central nervous system (CNS) dysfunction is more common in childhood-onset SLE.  CNS…
  • Abstract Number: 2618 • 2012 ACR/ARHP Annual Meeting

    Lupus Disease Activity Severely Impairs Pandemic Influenza A/H1N1 Vaccine Immune Response in Patients without Therapy

    Eduardo F. Borba1, Sandra G. Pasoto1, Ana L. Calich1, Ricardo Fuller1, Vilma S.T. Viana1, Margareth Vendramini1, Joao Miraglia2, Maria A. Ishida3 and Eloisa Bonfa4, 1Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, 2Instituto Butantan, Fundação Butantan, São Paulo, Brazil, 3Instituto Adolfo Lutz, São Paulo, Brazil, 4Rheumatology Division, University of São Paulo, Sao Paulo, Brazil

    Background/Purpose: To determine the influence of disease activity without the effect of drugs in pandemic 2009 influenza A (H1N1) vaccine immune response in untreated systemic…
  • Abstract Number: 216 • 2012 ACR/ARHP Annual Meeting

    Clinical and Serological Associations of Malignancy in Adult Patients with Polymyositis and Dermatomyositis

    Yuji Hosono1, Ran Nakashima1, Yoshitaka Imura2, Naoichiro Yukawa3, Hajime Yoshifuji1, Motomu Hashimoto4, Koichiro Ohmura5, Takao Fujii6 and Tsuneyo Mimori1, 1Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 3Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 4The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5Rheumatology & Clin Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 6Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are systemic connective tissue disorders, which are often associated with internal malignancy. Several studies have reported the association between…
  • Abstract Number: 2598 • 2012 ACR/ARHP Annual Meeting

    Anti-Drug Antibodies Are Associated with Diminished Drug Levels and Treatment Failure

    Miha Kosmac1, Natasa Toplak2, Gabriele Simonini3, Ilaria Pagnini4, Rolando Cimaz5, Vladka Curin Serbec1 and Tadej Avcin5, 1Research and Development Unit, Blood Transfusion Centre of Slovenia, Ljubljana, Slovenia, 2Department of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital Ljubljana Slovenia, Ljubljana, Slovenia, 3Rheumatology Unit-Department of Paediatrics, A. Meyer Children's Hospital, Florence, Italy, 4Rheumatoloy Unit, Anna Meyer Children's Hospital, Department of Pediatrics, University of Florence, Florence, Italy, 5Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: Due to their proteinaceus character biologics can often induce an unwanted immune response that results in the formation of anti-drug antibodies in patients receiving…
  • Abstract Number: 1941 • 2012 ACR/ARHP Annual Meeting

    Clinical Evaluation of Anti-Aminoacyl tRNA Synthetase Antibodies in Japanese Patients with Connective Tissue Diseases

    Masakazu Matsushita, Toshio Kawamoto, Ken Yamaji, Naoto Tamura and Yoshinari Takasaki, Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

    Background/Purpose: Anti-Jo-1 antibody is an autoantibody specifically detected in sera of patients with polymyositis/dermatomyositis (PM/DM). The antigen corresponding to this autoantibody is histidyl-tRNA synthase, being…
  • Abstract Number: 1936 • 2012 ACR/ARHP Annual Meeting

    The Human Leukocyte Antigen DRB1*13:02-DQB1*06:04-DPB1*04:01 Haplotype Is Closely Associated with Dermatomyositis Patients with Anti-CADM-140 (Melanoma Differentiation-Associated Protein 5: MDA5) Antibody

    Yuji Hosono1, Chikashi Terao2, Ran Nakashima1, Yoshitaka Imura3, Naoichiro Yukawa4, Hajime Yoshifuji1, Motomu Hashimoto5, Koichiro Ohmura6, Takao Fujii7 and Tsuneyo Mimori1, 1Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Center for Genomic Medicine, Kyoto University, Kyoto, Japan, 3Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Dept of Rheum & Clinical Immun, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 6Rheumatology & Clin Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 7Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Background/Purpose: Recent studies have revealed that anti-CADM-140 (MDA5/IFIH1)-antibody positive dermatomyositis (DM) patients frequently develop acute or subacute progressive interstitial pneumonia (A/SIP) with poor prognosis. However,…
  • Abstract Number: 1748 • 2012 ACR/ARHP Annual Meeting

    Antibody Secreting Cells Arising After Vaccination of Lupus Patients May Produce High Affinity Autoantibodies

    Kenneth Smith1, Jennifer Muther1, Angie Duke1, Emily McKee1, Alina Lorant1, Patrick C. Wilson2 and Judith A. James3, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Rheumatology and Knapp center for Lupus and Immunology Research, University of Chicago, Chicago, IL, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Vaccinating SLE patients with influenza and pneumococcal vaccines is generally considered safe and effective.  However, conflicting reports regarding the impact of vaccination on autoantibody…
  • Abstract Number: 1491 • 2012 ACR/ARHP Annual Meeting

    Systemic Sclerosis – Effects of Agonistic Autoantibodies Directed Against the Angiotensin Receptor Type 1 and the Endothelin Receptor Type A On Effector Cells

    Jeannine Guenther1, Angela Kill2, Mike O. Becker3 and Gabriela Riemekasten4, 1Rheumatology/Clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, Berlin, Germany, 2Rheumatology and clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, 3Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, 4Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany

    Background/Purpose: Autoimmunity, vasculopathy and fibrosis are features of systemic sclerosis (SSc). The functional link between these three pathophysiological components is still missing. Research suggests an…
  • Abstract Number: 1286 • 2012 ACR/ARHP Annual Meeting

    Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab

    Chad Pool1, Gopi Shankar2, Allen Schantz2, George Gunn2, Rebecca Bolce3, Marjatta Leirisalo-Repo4, Jim Wang1, John A. Goldman5, Raphael J. DeHoratius6, Roy Fleischmann7 and Dennis Decktor6, 1Janssen Services, LLC, Horsham, PA, 2Janssen R&D, LLC, PA, 3Crescendo Bioscience Inc., South San Francisco, CA, 4Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, 5Medical Quarters #293, Atlanta, GA, 6Medical Affairs, Janssen Services, LLC, Horsham, PA, 7Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: To determine if RA patients (pts) who had an inadequate response to etanercept(ETN) or adalimumab(ADA) and developed antibodies (Abs) to ETN or ADA responded…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology